{
    "id": 20100,
    "fullName": "KMT2A - MLLT1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KMT2A-MLLT1 (also referred to as MLL-ENL) results from the fusion of KMT2A and MLLT1, resulting in transformation in culture and leukemogenesis in mouse models (PMID: 9250666).",
            "references": [
                {
                    "id": 5009,
                    "pubMedId": 9250666,
                    "title": "Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9250666"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4297,
        "geneSymbol": "KMT2A",
        "terms": [
            "KMT2A",
            "ALL-1",
            "CXXC7",
            "HRX",
            "HTRX1",
            "MLL",
            "MLL1",
            "MLL1A",
            "TRX1",
            "WDSTS"
        ]
    },
    "variant": "KMT2A - MLLT1",
    "createDate": "03/24/2016",
    "updateDate": "07/25/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4298,
                "geneSymbol": "MLLT1",
                "terms": [
                    "MLLT1",
                    "ENL",
                    "LTG19",
                    "YEATS1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11493,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line harboring KMT2A-MLLT1 (MLL-ENL) in culture (PMID: 25817203).",
            "molecularProfile": {
                "id": 20541,
                "profileName": "KMT2A - MLLT1"
            },
            "therapy": {
                "id": 6006,
                "therapyName": "MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9548,
                    "pubMedId": 25817203,
                    "title": "Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25817203"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12169,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",
            "molecularProfile": {
                "id": 20552,
                "profileName": "KMT2A - MLLT1 NRAS G12D"
            },
            "therapy": {
                "id": 2880,
                "therapyName": "AZ20",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10122,
                    "pubMedId": 27625305,
                    "title": "Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27625305"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12168,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",
            "molecularProfile": {
                "id": 20552,
                "profileName": "KMT2A - MLLT1 NRAS G12D"
            },
            "therapy": {
                "id": 3557,
                "therapyName": "AZD0156",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10122,
                    "pubMedId": 27625305,
                    "title": "Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27625305"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5311,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).",
            "molecularProfile": {
                "id": 20552,
                "profileName": "KMT2A - MLLT1 NRAS G12D"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5010,
                    "pubMedId": 26627013,
                    "title": "The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627013"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11708,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Abcb1 was identified as the primary mechanism of acquired Pinometostat (EPZ-5676)-resistance in leukemia cell lines harboring KMT2A-MLLT1 (MLL-ENL) fusion in culture (PMID: 28428443).",
            "molecularProfile": {
                "id": 28187,
                "profileName": "KMT2A - MLLT1 ABCB1 over exp"
            },
            "therapy": {
                "id": 2855,
                "therapyName": "Pinometostat",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9714,
                    "pubMedId": 28428443,
                    "title": "Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28428443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20541,
            "profileName": "KMT2A - MLLT1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20552,
            "profileName": "KMT2A - MLLT1 NRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28187,
            "profileName": "KMT2A - MLLT1 ABCB1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}